Related Experiment Videos
Galactorrhea during duloxetine treatment: a case report
Sevda Korkmaz1, Murat Kuloğlu, Umut Işık
1Elazığ Psychiatry Hospital. skorkmaz23@hotmail.com
Turk Psikiyatri Dergisi = Turkish Journal of Psychiatry
|August 27, 2011
Summary
High prolactin hormone levels, known as hyperprolactinemia, can cause galactorrhea (milky nipple discharge). This case study highlights antidepressant duloxetine as a potential cause of hyperprolactinemia and galactorrhea in patients with depression.
Area of Science:
- Endocrinology
- Pharmacology
- Reproductive Medicine
Background:
- Hyperprolactinemia, elevated prolactin levels, is a common endocrine disorder.
- Galactorrhea, spontaneous milk production, is a primary symptom of hyperprolactinemia.
- Various factors, including medications, can induce hyperprolactinemia.
Observation:
- A case of hyperprolactinemia presenting with galactorrhea is reported.
- The patient was undergoing treatment for depression with duloxetine.
- Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI).
Findings:
- The patient's hyperprolactinemia and galactorrhea were directly linked to duloxetine therapy.
- Discontinuation of duloxetine led to the resolution of symptoms.
- This suggests a causal relationship between duloxetine and drug-induced hyperprolactinemia.
Implications:
- Clinicians should consider antidepressant-induced hyperprolactinemia when evaluating galactorrhea.
- Awareness of this side effect is crucial for accurate diagnosis and management.
- Further research may elucidate the precise mechanisms of SSNRI-induced hyperprolactinemia.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: